Newsletter | May 7, 2020

05.07.20 -- What To Expect From FDA During, Post-Covid-19

Featured Editorial
Industry Insights
Biosimilars: Providing More Treatment Options

It is hoped that the development of biosimilars will lead to more competition, and, therefore, more accessible, cost-effective treatments — especially in rheumatology.

Don’t Let Insufficient Data Undermine Your CMO And CRO Selection Processes

Selecting a partner is challenging, but with the right information you can simplify your efforts and increase your likelihood of making the best decision. 

Expanding SPR Uses In Antibody Effector Function Determination

SPR can be implemented at early stages in screening and testing strategies in order to provide better, faster, and stronger analysis of drug candidates. In order to minimize risk, and to get “true” affinity in binding analysis, we have adopted the latest innovation in surface plasmon resonance (SPR) technology, Biacore 8K, to develop and qualify assays for monoclonal antibodies and other therapeutic proteins to ensure all critical quality attributes are set and controlled with accuracy and precision.

News Headlines